Literature DB >> 14727217

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz.

Lucía Gallego1, Pablo Barreiro, Rafael del Río, Daniel González de Requena, Apolinar Rodríguez-Albariño, Juan González-Lahoz, Vincent Soriano.   

Abstract

Ambulatory electroencephalogram monitoring was performed for 18 HIV-infected subjects treated with efavirenz with and without insomnia and for 13 healthy control subjects. All patients receiving efavirenz had longer sleep latencies and shorter duration of deep sleep, although poor sleepers also showed reduced sleep efficiency and shorter duration of rapid eye movement sleep. Efavirenz plasma levels were higher in patients with insomnia and/or reduced sleep efficiency.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14727217     DOI： 10.1086/380791

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  39 in total

1.  Association of Markers of Inflammation with Sleep and Physical Activity Among People Living with HIV or AIDS.

Authors:  Michael D Wirth; Jason R Jaggers; Wesley D Dudgeon; James R Hébert; Shawn D Youngstedt; Steven N Blair; Gregory A Hand
Journal:  AIDS Behav       Date:  2015-06

2.  Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

Authors:  Salvador Cabrera Figueroa; Alicia Iglesias Gómez; Almudena Sánchez Martín; María de la Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé; Miguel Cordero Sánchez
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Engagement in Care, Psychological Distress, and Resilience are Associated with Sleep Quality among HIV-Positive Gay, Bisexual, and Other Men Who Have Sex with Men.

Authors:  Martin J Downing; Steven T Houang; Roberta Scheinmann; Irene S Yoon; Mary Ann Chiasson; Sabina Hirshfield
Journal:  Sleep Health       Date:  2016-09-19

5.  Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?

Authors:  Elke Wynberg; Eleri Williams; Gareth Tudor-Williams; Hermione Lyall; Caroline Foster
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

Review 6.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

7.  Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.

Authors:  Daniel H Johnson; Tebeb Gebretsadik; Ayumi Shintani; Gail Mayo; Edward P Acosta; C Michael Stein; David W Haas
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

8.  Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.

Authors:  Cecilia M Shikuma; Lindsay Kohorn; Robert Paul; Dominic C Chow; Kalpana J Kallianpur; Maegen Walker; Scott Souza; Louie Mar A Gangcuangco; Beau K Nakamoto; Francis D Pien; Timothy Duerler; Linda Castro; Lorna Nagamine; Bruce Soll
Journal:  HIV Clin Trials       Date:  2018-11-19

Review 9.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

10.  The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.

Authors:  Filip Josephson; Maria C H Andersson; Leo Flamholc; Magnus Gisslén; Lars Hagberg; Vidar Ormaasen; Anders Sönnerborg; Jan Vesterbacka; Ylva Böttiger
Journal:  Eur J Clin Pharmacol       Date:  2009-12-05       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.